Those concerned about the future of Boston’s biotech sector ought to read this NYT piece by Jacob Dreyer, who sounds the alarm and yet at the same time welcomes what the Chinese are doing to produce better, faster and cheaper drugs. He thinks China’s less expensive drugs will ultimately prove too irresistible for European and American consumers – and so the Chinese competitive threat is not going away. What should American biotech firms competitively do in response? Learn from the Chinese, just as the Chinese are eagerly learning from us, Dreyer says.

And here’s how not to respond to the Chinese competitive threat, also via the NYT:  “America Is Abandoning One of the Greatest Medical Breakthroughs.”